Platinum-sensitivity in metastatic colorectal cancer: Towards a definition
- 1 December 2013
- journal article
- Published by Elsevier BV in European Journal Of Cancer
- Vol. 49 (18), 3813-3820
- https://doi.org/10.1016/j.ejca.2013.07.150
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trialThe Lancet Oncology, 2011
- Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 StudyJournal of Clinical Oncology, 2009
- Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- The performance of different propensity-score methods for estimating relative risksJournal of Clinical Epidemiology, 2008
- Reintroduction of Oxaliplatin Is Associated With Improved Survival in Advanced Colorectal CancerJournal of Clinical Oncology, 2007
- Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200Journal of Clinical Oncology, 2007
- OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR StudyJournal of Clinical Oncology, 2006
- Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancerAnnals Of Oncology, 2004
- Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compoundsGynecologic Oncology, 1990
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983